Clearmind Medicine has entered an exclusive licensing agreement with the Yissum Research Development Company of the Hebrew University of Jerusalem to advance the development of Generation 3.0 psychedelic compounds for treating mental disorders.
This move signifies a key advancement in the field of psychedelic therapeutics, particularly for addiction and mental health treatments.
Go deeper with GlobalData
Clearmind will hold exclusive global rights for the development, research, manufacturing, marketing and commercialisation of products obtained from the synthesis of psychedelic compounds.
The strategic partnership will enhance Clearmind’s novel portfolio in addiction and mental disorders.
Clearmind is focused on the discovery and development of new psychedelic-derived therapeutics to manage health issues such as alcohol use disorder (AUD).
The company is working on transforming psychedelic-based compounds into regulated medicines, foods or supplements through research and development.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIts intellectual property (IP) portfolio comprises sixteen patent families.
Clearmind CEO Dr Adi Zuloff-Shani stated: “We believe that these new generation 3.0 compounds hold enormous therapeutic potential, as well as a strong safety profile.”
“The exclusive licensing agreement with Yissum expands our IP portfolio of highly differentiated assets, strengthens our leadership position with potentially first-in-class assets and illustrates our ongoing commitment to innovation.”
Last month, the company received approval from the Israeli Ministry of Health to begin its Phase I/IIa clinical trial of the 5-methoxy-2-aminoindane-based CMND-100 oral capsule for AUD.
This multinational, multi-centre, single and multiple-dose trial will conduct a comprehensive assessment of the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and AUD subjects.
